Fatigue News and Research

RSS

Merck update on the status of telcagepant clinical development programs

Merck & Co., Inc. today updated the status of the clinical development programs for telcagepant (MK-0974) and MK-3207, the Company's investigational oral calcitonin gene-related peptide (CGRP) receptor antagonists for the intermittent treatment of acute migraine.

11 Sep 2009

'How Much Longer' campaign for promoting autism awareness

The National Autism Association (NAA) declared today as National "How Much Longer" Day for Autism, a day of letter-writing to the media, health agencies, Department of Education, lawmakers and the Obama Administration asking for such things as health insurance coverage, federal laws to protect special-ed students from dangerous restraint and seclusion practices in schools, safer vaccines, and for autism to be declared a nation health crisis.

10 Sep 2009

New protocol to tackle postpartum depression

Up to 80 percent of women experience depressive symptoms postpartum, with one in eight reporting the emergence of major depression within weeks of delivery.

10 Sep 2009

GlaxoSmithKline's CERVARIX receives favorable recommendation from FDA Advisory Committee

GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that clinical data support both the efficacy and safety of CERVARIX((R)), the company's candidate cervical cancer vaccine (12-1 and 11-1, respectively).

10 Sep 2009

Global AIDS Coordinator Goosby believes Zimbabwe's ailing health system can be strengthened

Concluding his recent trip to Zimbabwe, the Global AIDS Coordinator for PEPFAR Eric Goosby said the country can rebuild and strengthen its health care delivery systems, the Zimbabwean reports. "I have seen fatigue in health care delivery in the country. A fatigue that that has come out of sustaining the response (to HIV and AIDS) with diminishing resources, but at the same time a feeling of hope and anticipation that they have hit bottom and are now on the return," Goosby said (9/4).

9 Sep 2009

Research study examines the depression rate in chronic kidney disease patients

One in five patients with chronic kidney disease is depressed, even before beginning long-term dialysis therapy or developing end-stage renal disease, UT Southwestern Medical Center researchers have found.

9 Sep 2009

Parents use many food strategies to cope with work and family demands

Since most parents in the US are employed, there are competing demands on their time that can compromise food choices for themselves and their children. How parents cope with these demands and how work conditions are related to food choice coping strategies are the subjects of a study in the September/October issue of the Journal of Nutrition Education and Behavior.

9 Sep 2009

Muscular Dystrophy Canada to host the 44th Jerry Lewis Labour Day Telethon

Muscular Dystrophy Canada is hosting the 44th Annual Jerry Lewis Labour Day Telethon to support those living with a neuromuscular disorder.

7 Sep 2009

Shire receives FDA approval for INTUNIV extended release tablets

Shire plc, the global specialty biopharmaceutical company, today announced that it has received approval from the US Food and Drug Administration (FDA) for INTUNIV(TM) (guanfacine) Extended Release Tablets for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years.

4 Sep 2009

Educating teenagers could lower accident risk, says NRSF

As millions of teens head back to school, many will be driving to and from classes every day.

3 Sep 2009

Phase I clinical trial data of GDC-0449 published in the New England Journal Of Medicine

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines for cancer treatment, today announced that two publications describing clinical data generated with GDC-0449 were published in the current edition of The New England Journal of Medicine (NEJM).

3 Sep 2009

Medtronic's COPE-HCV clinical study commences

Medtronic, Inc., today reported the initiation and first enrollments of patients in COPE-HCV (COntinuous Interferon Delivery via the Medtronic Paradigm Pump Infusion System Clinical Evaluation for Chronic HCV), the company’s first-ever clinical study using an external pump infusion system to treat patients with the hepatitis C virus (HCV).

3 Sep 2009

GDC-0449 inhibits the Hedgehog signaling pathway

The Hedgehog signaling pathway is involved in a preliminary study and case report describing positive responses to an experimental anticancer drug in a majority of people with advanced or metastatic basal cell skin cancers. One patient with the most common type of pediatric brain cancer, medulloblastoma, also showed tumor shrinkage.

3 Sep 2009

CIF launches campaign by distributing a "Ten Tips "card to help parents easily identify potential life threatening injuries

As high school student-athletes begin the academic year and participate in double-day sports practices statewide, the California Interscholastic Federation is drawing attention to the health risks associated with concussions, heat stroke and dehydration.

3 Sep 2009

Wallet-sized cards offer athletes tips for detecting and monitoring concussions

In response to a rising number of concussions and recent research which shows young athletes with repeated brain injuries are at great risk for future neurological problems, the Illinois Athletic Trainers Association (IATA) and the Chicago Institute of Neurosurgery and Neuroresearch (CINN) are offering a wallet-sized card with tips for detecting and monitoring concussions. The complimentary card is an educational tool for parents, coaches and others who work with young athletes to help them identify signs of a concussion.

2 Sep 2009

Neuromuscular disorders common among Canadians

September is Muscular Dystrophy Awareness Month. There are more than 100 neuromuscular disorders and it is estimated more than 50,000 Canadians are affected by one form or another. Each form is caused by an error in a specific gene related to muscle function.

2 Sep 2009

FDA: Randomized clinical trial necessary to better interpret Clolar’s efficacy and safety in adult AML

Genzyme Corporation (Nasdaq: GENZ) announced today that the FDA’s Oncologic Drugs Advisory Committee voted 9 to 3 that a randomized, controlled trial is needed to support the currently proposed label expansion for Clolar® (clofarabine) in adult myeloid leukemia (AML). The committee found that the single-arm clinical study results submitted to support the label expansion showed Clolar was an active agent in acute AML patients, but concluded that a randomized clinical trial should be necessary to better interpret Clolar’s efficacy and safety in the proposed patient population.

2 Sep 2009

New therapy delays the progression of heart failure

A therapy called cardiac resynchronization can significantly delay the progression of heart failure, according to a major international study published in the New England Journal of Medicine.

2 Sep 2009

MammoSite ML radiation therapy system approved for breast cancer treatment

Hologic, Inc. (Hologic or the Company), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced the U.S. Food and Drug Administration (FDA) cleared the Company's 510K application for the MammoSite((R)) ML radiation therapy system.

1 Sep 2009

Cimzia approved for treating adult patients with rheumatoid arthritis

UCB Canada Inc. announced today that Health Canada has approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

1 Sep 2009